KLK3 and prostate carcinoma: Given the high and prolonged efficacy of ADT in castration sensitive prostate cancer, patients receiving ADT in addition to MDT will experience significant and prolonged suppression of PSA levels regardless of the efficacy of the image-guided intervention.